Effect of Piroxicam in In-vitro Fertilization cycle success

Evaluation of Piroxicam effect in frozen embryo transfer cycle in fertility and success rate of In-vitro Fertilization cycle

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120708010210N8

Enrollment

180

Registered

2020-01-10

Start date

2019-12-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility patients going ivf cycle with frozen embryo. Female infertility

Interventions

Intervention 1: Intervention group: Consumption of 10 mg po Piroxicam 1-2 hour befor embryo transfer. Intervention 2: Control group: consumption of placebo 1 to 2 hour befor embryo transfer.

Eligibility

Sex/Gender

Female

Age

18 Years to 42 Years

Inclusion criteria

Inclusion criteria: Informed consent Infertile women planned for IVF Normal Endometrial cavity High quantity freezed embryos

Exclusion criteria

Exclusion criteria: Aspirin sensitive asthma Anemia or coagulopathy disorders Liver or Renal failure Ischemic Heart disease or Heart Failure Hypertention and Cerebrovascular Diseases Allergy to NSAIDS Peptic Ulcer Disease or positive history of GI bleeding Traumatic embryo transfer

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate. Timepoint: 2 months after embryo transfer. Method of measurement: Ultrasonography.;Chemical pregnancy rate. Timepoint: 14 days after transferring the embryo. Method of measurement: Pregnancy Test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNahid Homayoun

Shiraz University of Medical Sciences

Nahidd.homayoun@gmail.com+98 71 3631 5025

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026